"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 31 | 31 |
| 2004 | 0 | 61 | 61 |
| 2005 | 1 | 60 | 61 |
| 2006 | 0 | 64 | 64 |
| 2007 | 0 | 92 | 92 |
| 2008 | 0 | 78 | 78 |
| 2009 | 1 | 95 | 96 |
| 2010 | 1 | 106 | 107 |
| 2011 | 0 | 88 | 88 |
| 2012 | 1 | 116 | 117 |
| 2013 | 0 | 111 | 111 |
| 2014 | 1 | 130 | 131 |
| 2015 | 0 | 125 | 125 |
| 2016 | 0 | 122 | 122 |
| 2017 | 0 | 105 | 105 |
| 2018 | 0 | 102 | 102 |
| 2019 | 1 | 97 | 98 |
| 2020 | 0 | 83 | 83 |
| 2021 | 0 | 81 | 81 |
| 2022 | 0 | 28 | 28 |
| 2023 | 0 | 32 | 32 |
| 2024 | 0 | 73 | 73 |
| 2025 | 0 | 74 | 74 |
| 2026 | 0 | 54 | 54 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Mitochondrial metabolic reprogramming by a glutamine antagonist radioenhancer conjugate drives pyroptosis and antitumor immunity. Sci Adv. 2026 Oct 30; 12(44):eaeh5903.
-
TEDEdb: A multicohort analysis and resource for transposable element differential expression in cancer. Proc Natl Acad Sci U S A. 2026 Nov 03; 123(44):e2615533123.
-
Thymol-based derivatives as anticancer agents: design, synthesis, biological evaluation, and molecular docking studies. Bioorg Chem. 2026 Nov 05; 183:110587.
-
Assessing the Mutational Consequences of Chronic Arsenic Exposure Using Patient-Derived Tumor Samples and In Vitro Systems. Environ Mol Mutagen. 2026 Oct-Nov; 67(8-9).
-
Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis. Cancer Cell. 2026 Oct 12; 44(10):2011-2028.e7.
-
Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent. Sci Adv. 2026 Sep 11; 12(37):eadz6815.
-
PARP16 is a druggable regulator of ribosome MARylation and protein homeostasis in ovarian cancer cells. J Biol Chem. 2026 Oct; 302(10):113540.
-
Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy-Resistant Breast Cancer. Mol Cancer Res. 2026 Sep 02; 24(9):784-800.
-
Galanin impairs tumor immunity in glioblastoma by promoting infiltration and ferroptosis resistance of myeloid-derived suppressor cells. Nat Cancer. 2026 Sep; 7(9):1387-1405.
-
CD73 inhibition overcomes adaptive immune resistance to PARP inhibition in models of prostate cancer. J Clin Invest. 2026 Oct 01; 136(19).